JP2023057069A - 蛍光ｖｈｈ抗体 - Google Patents

蛍光ｖｈｈ抗体 Download PDF

Info

Publication number
JP2023057069A
JP2023057069A JP2022162701A JP2022162701A JP2023057069A JP 2023057069 A JP2023057069 A JP 2023057069A JP 2022162701 A JP2022162701 A JP 2022162701A JP 2022162701 A JP2022162701 A JP 2022162701A JP 2023057069 A JP2023057069 A JP 2023057069A
Authority
JP
Japan
Prior art keywords
amino acid
vhh antibody
vhh
fluorescent protein
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022162701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023057069A5 (enExample
Inventor
篤 長見
Atsushi Nagami
峻亮 稲浦
Shunsuke Inaura
拓也 森本
Takuya Morimoto
和彦 片山
Kazuhiko Katayama
慧 芳賀
Satoshi Haga
玲子 戸高
Reiko Todaka
敦史 宮脇
Atsushi Miyawaki
哲 下薗
Satoru Shimozono
真由 杉山
Masayoshi Sugiyama
裕 濱
Yutaka Hama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Kitasato University
RIKEN
Original Assignee
Kao Corp
Kitasato University
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp, Kitasato University, RIKEN filed Critical Kao Corp
Publication of JP2023057069A publication Critical patent/JP2023057069A/ja
Publication of JP2023057069A5 publication Critical patent/JP2023057069A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022162701A 2021-10-08 2022-10-07 蛍光ｖｈｈ抗体 Pending JP2023057069A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021166259 2021-10-08
JP2021166259 2021-10-08

Publications (2)

Publication Number Publication Date
JP2023057069A true JP2023057069A (ja) 2023-04-20
JP2023057069A5 JP2023057069A5 (enExample) 2025-10-14

Family

ID=85804377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022162701A Pending JP2023057069A (ja) 2021-10-08 2022-10-07 蛍光ｖｈｈ抗体

Country Status (2)

Country Link
JP (1) JP2023057069A (enExample)
WO (1) WO2023058762A1 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111236A1 (ja) * 2003-06-16 2004-12-23 Riken 蛍光蛋白質
WO2015025959A1 (ja) * 2013-08-23 2015-02-26 独立行政法人理化学研究所 蛍光特性を示すポリペプチド、およびその利用
CN111647076A (zh) * 2020-04-27 2020-09-11 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用
CN112062838A (zh) * 2020-08-25 2020-12-11 南京医科大学 一种抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用
CN113307865A (zh) * 2020-02-26 2021-08-27 复旦大学 新型冠状病毒的全人源单域抗体及应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111236A1 (ja) * 2003-06-16 2004-12-23 Riken 蛍光蛋白質
WO2015025959A1 (ja) * 2013-08-23 2015-02-26 独立行政法人理化学研究所 蛍光特性を示すポリペプチド、およびその利用
CN113307865A (zh) * 2020-02-26 2021-08-27 复旦大学 新型冠状病毒的全人源单域抗体及应用
CN111647076A (zh) * 2020-04-27 2020-09-11 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用
CN112062838A (zh) * 2020-08-25 2020-12-11 南京医科大学 一种抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRONTIER IN IMMUNOLOGY, vol. Vol. 8, Article 1030 (8 pages), JPN6026026130, 2017, ISSN: 0005896542 *

Also Published As

Publication number Publication date
WO2023058762A1 (ja) 2023-04-13

Similar Documents

Publication Publication Date Title
CN113195516B (zh) 由特异性结合物识别的表位标签
KR101682257B1 (ko) 인간 ｃｘｃｌ１ 단백질의 면역학적 측정 방법
EP2663642B1 (en) Treponema pallidum triplet antigen
JP2018529310A (ja) ジユビキチン変異タンパク質に基づくＨｅｒ２結合タンパク質
JP2019163270A (ja) 親和性タンパク質及びその使用
KR101571940B1 (ko) 면역성 혈소판 감소증과 관련된 모에신 단편
KR102660061B1 (ko) 항 열대열 말라리아 원충 hrp-ii 항체
US20240117012A1 (en) Anti-sars-cov-2 antibody
KR20240170809A (ko) 캐스케이드 효소 반응에 의한 pal-촉매화된 단백질 라이게이션 효율 개선
WO2023058762A1 (ja) 蛍光ｖｈｈ抗体
CN113528569A (zh) 一种利用isPLA高通量筛选单域抗体的方法及其应用
CN107108723B (zh) 精氨基琥珀酸合成酶的抗体和相关方法
JP7414225B2 (ja) ＳＡＲＳ－ＣｏＶ－２結合ペプチド
CN103124904B (zh) 食蟹猴ccl17
CN114430747A (zh) 抗csf-1r抗体
JP2006340717A (ja) Ｇタンパク質共役型受容体に対する結合性評価方法及び評価用組成物、融合タンパク質、並びに、遺伝子
US20250382358A1 (en) Methods and compositions relating to mouse monoclonal anti-g4s linker antibodies
CN113087807B (zh) 用于检测糖类抗原的基于志贺毒素b亚基重组蛋白的探针、制备方法
CA3230197A1 (en) Fluorescent sensor for monitoring calcium dynamics
RU2788083C2 (ru) Пептид для лечения возрастной макулярной дегенерации
CN118496370A (zh) 一种靶向alox5纳米抗体及其应用
WO2025232872A1 (zh) 融合抗原及其应用
Dübel Delivery of antibodies to the cytosol
JP2011125318A (ja) 特定部位のアミノ酸を置換した緑色蛍光蛋白質またはそのホモログを用いたカルシウムセンサー蛋白質
Marschall et al. Delivery of antibodies to the cytosol

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260630